TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Peptilogics Announces First Patient Dosed in Phase 1b Study of PLG0206 for Periprosthetic Joint Infection

Friday, October 07, 2022

Peptilogics, a clinical-stage biotech company specializing in peptide therapeutic solutions for patients with life-threatening diseases, has announced the dosing of its first patient with PLG0206 in the LOGIC-1 trial. This trial aims to evaluate the efficacy of PLG0206 in treating periprosthetic joint infections (PJI) that occur following total knee arthroplasty (TKA). PLG0206, an investigational product, has been granted several designations by the FDA, including Orphan Drug, Fast Track, and Qualified Infectious Disease Product (QIDP) for the treatment of PJI.

Dr. David Huang, Chief Medical Officer of Peptilogics, expressed satisfaction with the dosing of the first patient in the Phase 1b study and highlighted the potential of PLG0206 to improve clinical outcomes for patients suffering from PJIs after joint replacement. Dr. Matthew Dietz, Coordinating Investigator for the study and an orthopedic surgeon at WVU Medicine Orthopaedics, emphasized the significance of using PLG0206 to treat prosthetic joint infections, which has been a longstanding challenge for the orthopedic community.

Each year, millions of total joint replacements are performed in the U.S., and the incidence is expected to rise significantly by 2030. However, periprosthetic joint infections pose a severe threat to patients, often requiring prolonged antibiotic usage, multiple high-risk surgical procedures, and even implant removal, with limited success in resolving the infection. The current standard of care has shown a failure rate of up to 60% at four years and a five-year mortality rate of 25%. Peptilogics aims to redefine the treatment paradigm for PJI and differentiate PLG0206 from existing therapeutic options.

Jonathan Steckbeck, Founder and CEO of Peptilogics, expressed optimism about reaching this significant milestone with their first program. He highlighted PLG0206's potential as a best-in-class treatment option, demonstrating rapid bactericidal activity and broad-spectrum efficacy against various biofilm pathogens in preclinical studies. The safety of PLG0206 has also been established in a previously completed Phase 1 study involving healthy volunteers. Steckbeck emphasized the importance of evaluating PLG0206's impact on patients with limited and often ineffective treatment options for PJI, setting a precedent for future programs.

The LOGIC-1 trial is an open-label, dose-escalating Phase 1b study involving individuals undergoing debridement, antibiotics, and implant retention (DAIR) surgical procedures for the treatment of PJI following total knee arthroplasty. For more information about the trial, interested individuals can visit www.clinicaltrials.gov and use the study identifier NCT05137314.

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit